New polymyxin B dosing strategies to fortify old allies in the war against KPC-2-producing klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Bulman, Zackery P ^a   Satlin, Michael J ^b   Chen, Liang ^c   Kreiswirth, Barry N ^c   Shin, Beom Soo ^d   Walsh, Thomas J ^b   Holden, Patricia N ^a   Forrest, Alan ^e   Nation, Roger L ^f   Li, Jian ^f   Tsujia, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d Catholic University of Daegu   (South Korea)

^e UNC Hamner Institute for Drug Safety Sciences   (United States)

^f MONASH UNIVERSITY   (Australia)

Author keywords

KPC producing K. pneumoniae; Meropenem; PK PD; Polymyxin B; Rifampin

Indexed keywords

MEROPENEM; POLYMYXIN B; RIFAMPICIN; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BROTH DILUTION; COLONY FORMING UNIT; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG HALF LIFE; HUMAN; KLEBSIELLA PNEUMONIAE; LIMIT OF QUANTITATION; LOADING DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SEPTIC SHOCK; SINGLE DRUG DOSE; UNBOUND FRACTION; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; COMBINATION DRUG THERAPY; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; COLONY COUNT, MICROBIAL; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; POLYMYXIN B; RIFAMPIN; THIENAMYCINS;

EID: 85016992159     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02023-16     Document Type: Article

References (44)

1. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. 2011. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17: 1798-1803. https://doi.org/10.1111/j.1469 -0691.2011.03514.x.
2. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108-2113. https://doi.org/10.1128/AAC.06268-11.
3. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13: 785-796. https://doi.org/10.1016/S1473-3099(13)70190-7.
4. Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, Oethinger M, Paterson DL, Adams MD, Jacobs MR, Diekema DJ, Hall GS, Jenkins SG, Rice LB, Tenover FC, Bonomo RA. 2009. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 63: 427-437. https://doi.org/10.1093/jac/dkn547.
5. Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF. 2015. Correlation of beta-lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program. Antimicrob Agents Chemother 60: 1385-1392. https://doi.org/10.1128/AAC.01870-15.
6. de Oliveira MS, de Assis DB, Freire MP, Boas do Prado GV, Machado AS, Abdala E, Pierrotti LC, Mangini C, Campos L, Caiaffa Filho HH, Levin AS. 2015. Treatment of KPC-producing Enterobacteriaceae: Suboptimal efficacy of polymyxins. Clin Microbiol Infect 21: 179.e171-179.e177. https://doi.org/10.1016/j.cmi.2014.07.010.
7. Tsuji BT, Landersdorfer CB, Lenhard JR, Cheah SE, Thamlikitkul V, Rao GG, Holden PN, Forrest A, Bulitta JB, Nation RL, Li J. 2016. Paradoxical effect of polymyxin B: High drug exposure amplifies resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 60: 3913-3920. https://doi.org/10.1128/AAC.02831-15.
8. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P. 2015. Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70: 2133-2143.
9. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemaseproducing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58: 2322-2328. https://doi.org/10.1128/AAC.02166-13.
10. Gomez-Simmonds A, Nelson B, Eiras DP, Loo A, Jenkins SG, Whittier S, Calfee DP, Satlin MJ, Kubin CJ, Furuya EY. 4 April 2016. Combination regimens for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother https://doi.org/10.1128/aac.03007-15.
11. Michail G, Labrou M, Pitiriga V, Manousaka S, Sakellaridis N, Tsakris A, Pournaras S. 2013. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 57: 6028-6033. https://doi.org/10.1128/AAC.00891-13.
12. Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, Ambretti S. 2014. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPCproducing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 69: 1856-1865. https://doi.org/10.1093/jac/dku065.
13. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. 2011. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 55: 1420-1427. https://doi.org/10.1128/AAC.01253-10.
14. CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-10th edition. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, Feldman EJ, Roboz GJ, Shore TB, Helfgott DC, Soave R, Kreiswirth BN, Walsh TJ. 2013. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 54: 799-806. https://doi.org/10.3109/10428194.2012.723210.
16. Eisner A, Fagan EJ, Feierl G, Kessler HH, Marth E, Livermore DM, Woodford N. 2006. Emergence of Enterobacteriaceae isolates producing CTX-M extended-spectrum beta-lactamase in Austria. Antimicrob Agents Chemother 50: 785-787. https://doi.org/10.1128/AAC.50.2.785-787.2006.
17. Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70: 119-123. https://doi.org/10.1016/j.diagmicrobio.2010.12.002.
18. Chen L, Mediavilla JR, Endimiani A, Rosenthal ME, Zhao Y, Bonomo RA, Kreiswirth BN. 2011. Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants. J Clin Microbiol 49: 579-585. https://doi.org/10.1128/JCM.01588-10.
19. Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. 2006. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother 50: 3396-3406. https://doi.org/10.1128/AAC.00285-06.
20. Ly NS, Bulman ZP, Bulitta JB, Baron C, Rao GG, Holden PN, Li J, Sutton MD, Tsuji BT. 2016. Optimization of polymyxin B in combination with doripenem to combat mutator Pseudomonas aeruginosa. Antimicrob Agents Chemother 60: 2870-2880. https://doi.org/10.1128/AAC .02377-15.
21. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clin Infect Dis 57: 524-531. https://doi.org/10.1093/cid/cit334.
22. Munz MR BJ, Höhl R, Jensen A, Junger A, Glaser R, Stelzer C, Kinzig M, Bertsch T, Holzgrabe U, Sörgel F. 2015. Individualizing meropenem prolonged infusions in intensive care unit patients via population modeling of renal function and infection biomarkers over time. Abstr Paracelsus Sci Get Together, Nuremberg, Germany, July 3, 2015.
23. Sanofi. 2013. Rifadin (R) rifampin (package insert). Sanofi, Bridegwater, NJ.
24. Acocella G. 1978. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3: 108-127. https://doi.org/10.2165/00003088-197803020 -00002.
25. Pournaras S, Kristo I, Vrioni G, Ikonomidis A, Poulou A, Petropoulou D, Tsakris A. 2010. Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J Clin Microbiol 48: 2601-2604. https://doi.org/10.1128/JCM.02134-09.
26. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J. 2008. In vitro pharmacodynamics of colistin against multidrugresistant Klebsiella pneumoniae. J Antimicrob Chemother 62: 1311-1318. https://doi.org/10.1093/jac/dkn425.
27. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15(Suppl A): 125-130.
28. Cheah SE, Bulitta JB, Li J, Nation RL. 2014. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 92: 177-182. https://doi.org/10.1016/j.jpba.2014.01.015.
29. Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah S-E, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT. 15 September 2016. High-intensity meropenem combinations with polymyxin B: New strategies to overcome carbapenem resistance in Acinetobacter baumannii. J Antimicrob Chemother https://doi.org/10.1093/jac/dkw355.
30. Palmer SM, Rybak MJ. 1996. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother 40: 701-705.
31. Kitchel B, Rasheed JK, Endimiani A, Hujer AM, Anderson KF, Bonomo RA, Patel JB. 2010. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 54: 4201-4207. https://doi.org/10.1128/AAC.00008-10.
32. Landman D, Bratu S, Quale J. 2009. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol 58: 1303-1308. https://doi.org/10.1099/jmm.0.012575-0.
33. Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O. 2014. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 58: 1757-1762. https://doi.org/10.1128/AAC.00741-13.
34. Urban C, Mariano N, Rahal JJ. 2010. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrugresistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 54: 2732-2734. https://doi.org/10.1128/AAC.01768-09.
35. Velkov T, Deris ZZ, Huang JX, Azad MA, Butler M, Sivanesan S, Kaminskas LM, Dong YD, Boyd B, Baker MA, Cooper MA, Nation RL, Li J. 2014. Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae. Innate Immun 20: 350-363. https://doi.org/10.1177/1753425913493337.
36. Jayol A, Nordmann P, Brink A, Poirel L. 2015. Heteroresistance to colistin in Klebsiella pneumoniae associated with alterations in the PhoPQ regulatory system. Antimicrob Agents Chemother 59: 2780-2784. https://doi.org/10.1128/AAC.05055-14.
37. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 54: 804-810. https://doi.org/10.1128/AAC.01190-09.
38. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. 2012. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56: 3753-3757. https://doi.org/10.1128/AAC.05927-11.
39. Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, Drusano G, Shlaes D, Nichols WW. 2014. Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 58: 3366-3372. https://doi.org/10.1128/AAC.00080-14.
40. Bulik CC, Nicolau DP. 2011. Double-carbapenem therapy for carbapenemase- producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55: 3002-3004. https://doi.org/10.1128/AAC.01420-10.
41. Adler A, Ben-Dalak M, Chmelnitsky I, Carmeli Y. 2015. Effect of resistance mechanisms on the inoculum effect of carbapenem in Klebsiella pneumoniae isolates with borderline carbapenem resistance. Antimicrob Agents Chemother 59: 5014-5017. https://doi.org/10.1128/AAC.00533-15.
42. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57: 1300-1303. https://doi.org/10.1093/cid/cit453.
43. Forrest A. 2013. Towards optimized dosing of intravenous colistin and polymyxin B: Risk factors for nephrotoxicity. Proc 1st Int Conf Polymyxins, Prato, Italy.
44. Garonzik SM, Forrest A, Thamlikitkul V, Li J, Paterson DL, Silveira FP, Nation RL. 2011. Predictors of changes in renal function in critically-ill patients on colistin methanesulfonate, abstr A-1101, slide session 156. Abstr 51st Intersci Conf Antimicrob Agents Chemother, 17 to 20 September, Chicago, IL. American Society for Microbiology, Washington, DC.